Please login to the form below
Lars Rebien Sørensen becomes chairman of Novo Holdings
He will take up the new role 1 July
Former Novo Nordisk CEO Lars Rebien Sørensen has been appointed as Novo Holdings’ new chairman.
He said: “In recent years, Novo Holdings has significantly increased its investments and influence in the global life science sector.
“I consider it to be a great responsibility to lead the continued growth of Novo Holdings as it plans to further increase its investments in life science companies in the coming years.
Sørensen will succeed Sten Scheibye - who retires effective 1 July - and he will also become chairman of the board of the Novo Nordisk Foundation.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
-
Digital strategist
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Onyx Health Launch Creative Studio After Record Year
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Paving the way for the HCP omnichannel experience: a guide for medical affairs
- EU approves bluebird bio’s CALD gene therapy Skysona
- Ashfield Health announces three new senior hires
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
